Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Teva Pharmaceutical Industries Limited : Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 08:21pm CEST

IRVINE, CA / ACCESSWIRE / October 4, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Teva Pharmaceutical Industries Limited ("Teva" or the "Company") (NYSE: TEVA). Investors, who purchased or otherwise acquired shares from November 15, 2016 through August 2, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm before the October 23, 2017 lead plaintiff motion deadline.

If you purchased Teva shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, throughout the Class Period, Teva issued materially false and/or misleading statements, and/or failed to disclose, that the poor performance of its U.S. generics business resulted in the Company recording a goodwill impairment charge related to the acquisition of Actavis Generics and was a key factor in cutting Teva's dividend by 75%. When this information was released, shares of Teva fell in value materially, which caused investors harm according to the lawsuit.

If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]

SOURCE: Khang & Khang LLP


© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
07/20TEVA PHARMACEUTICAL INDUSTRIES : Highlights Key Milestones Achieved in the 2017 ..
AQ
07/19TEVA PHARMACEUTICAL INDUSTRIES : Announces Launch of a Generic Version of Uceris..
AQ
07/19TEVA PHARMACEUTICAL INDUSTRIES : Court allows closure of Teva's Ashdod plant
AQ
07/17PAXMAN PUBL : receives first order from Teva in Mexico for 17 scalp cooling syst..
AQ
07/17TEVA PHARMACEUTICAL INDUSTRIES : Highlights Key Milestones Achieved in the 2017 ..
BU
07/16TEVA PHARMACEUTICAL INDUSTRIES : Previous ArticleTeva Reports First Quarter 2018..
AQ
07/13TEVA PHARMACEUTICAL INDUSTRIES : FDA Recalls Several Medicines That Contain Vals..
DJ
07/13TEVA PHARMACEUTICAL INDUSTRIES : to Report Second Quarter 2018 Financial Results..
AQ
07/12TEVA PHARMACEUTICAL INDUSTRIES : Researchers at Teva Pharmaceutical Report New D..
AQ
07/12TEVA PHARMACEUTICAL INDUSTRIES : Mylan generic Copaxone price cut puzzles indust..
AQ
More news
News from SeekingAlpha
07/11YOUR DAILY PHARMA SCOOP : IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish 
07/11Big Pharma in the red after Pfizer backs away from price hikes 
07/10Pricing transparency law in California having effect, drug makers nix planned.. 
07/10Crinetics Pharmaceuticals Readies $80 Million IPO 
07/09Biotechs give up gains after Trump tweet on prices 
Financials ($)
Sales 2018 19 600 M
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 1,20x
Capi. / Sales 2019 1,20x
Capitalization 23 487 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 19,5 $
Spread / Average Target -16%
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani Executive Vice President-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED30.63%23 487
JOHNSON & JOHNSON-9.93%342 779
PFIZER3.06%220 295
NOVARTIS-1.75%206 001
ROCHE HOLDING LTD.-5.90%203 399
MERCK AND COMPANY11.11%169 328